Abstracts 2014
- OP001. Innate lymphoid cells accumulate in IBD
- OP002. The GCN2/eIF2α/ATF4 signaling pathway is necessary for autophagy response to infection with Crohn's disease-associated adherent-invasive Escherichia coli
- OP003. Circadian clock function maintains mucosal architecture and protects against intestinal inflammation in mice
- OP004. Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial
- OP005. Is elderly-onset ulcerative colitis a different entity? - Natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort
- OP006. Personalized thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients. Results from a randomized trial in the Netherlands
- OP007. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA stud
- OP008. The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era - An ECCO-EpiCom study
- OP009. Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
- OP010. AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis
- OP011. Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study
- OP012. Epigenetic control of colonic inflammation via the methyl-binding protein Mbd2
- OP013. Status of ER stress and autophagy in Crohn's disease: From genetics to functional read-outs
- OP014. Early endoscopic, laboratory and clinical predictors of poor disease course in pediatric ulcerative colitis (UC)
- OP015. Gut homing markers in perianal Crohn's fistulae
- OP016. Transethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between Europeans and non-Europeans
- OP017. Cross-disease study determines extent of sharing of associated loci between five seronegative auto-inflammatory diseases
- OP018. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a deficient commensal bacteria implicated in Crohn's disease
- OP019. Hypoxia responsive elements methylation status governs adherent-invasive Escherichia coli-receptor CEACAM6 expression in Crohn's disease
- OP020. 16S rRNA gene pyrosequencing indicate that siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities
- OP021. Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn's disease in the IMAgINE 1 trial
- OP022. Low microbial gene diversity and depletion of Akkermansia mucini-phila is associated with a relapsing course of ulcerative colitis
- OP023. Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study
- OP024. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease
- P001. miR-301a and miR-301b are highly expressed in inflamed mucosa of inflammatory bowel disease and promotes Th1/Th17 immune responses
- P002. miR-10a suppresses dendrite cell activation and Th1/Th17 cell responses in inflammatory bowel disease
- P003. Vitamin D deficiency enhances adherent invasive Escherichia coli induced barrier dysfunction and experimental colonic injury
- P004. Transcriptome of unfolded protein response (UPR) genes in the colonic mucosa of patients with ulcerative colitis
- P005. Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis
- P006. The therapeutic potential of the pharmacological inhibition of PBEF/NAMPT/Visfatin in inflammatory bowel disease
- P007. The ratio of circulating estrogen receptors beta and alpha (ERβ/ERα) indicates endoscopic activity in patients with Crohn's disease
- P008. The pro-apoptotic galectin-1 is functionally inhibited in inflamed intestinal areas of IBD patients
- P009. The long-term therapeutic effect of bone marrow-derived mesenchymal stem cells in a dextran sulfate sodium-induced murine colitis
- P010. The influence of vitamin D3 for colitis model of rats
- P011. The impact of omentectomy on the severity of colitis and adipocytokine expression
- P012. The effects of mesenchymal stem cells as a cell therapy in animal model of Crohn's disease
- P013. The effects of Schistosoma japonicum eggs antigen on SAMP1/Yit mice, a spontaneous ileitis model
- P014. The effect of the anti-TNFα adalimumab on the levels of angiogenic factors in mucosal cultures from patients with inflammatory bowel disease (IBD)
- P015. The VEGFC/VEGFR3 pathway controls colitis associated cancer formation and progression through lymphangio-genesis and lymphatic endothelial VE-cadherin
- P017. The effect of intestinal alkaline phosphatase on intestinal epithelial cells, macrophages and chronic colitis in interleukin-10-deficient mice
- P018. The anti-inflammatory cytokine IL-10 is an important mediator of the action of the TLR-9 agonist DIMS0150
- P019. T cell specific loss of PTPN2 results in aggravated colitis and pronounced intestinal dysbiosis as observed in Crohn's disease patients
- P020. Silencing of prolyl hydroxylase 1 in intestinal microvascular endothelial cells prevents inflammation-induced endothelial dysfunction and dampens murine colitis
- P021. Roxithromycin inhibits nuclear factor kappaB signaling and endoplasmic reticulum stress in intestinal epithelial cells, and ameliorates experimental colitis
- P022. Role of P2X7 purinergic receptor in the control of enteric neuromuscular functions in normal rat distal colon and experimental bowel inflammation
- P023. Regulation of colonic inflammation by commensal flora in SAMP1/YitFc mice
- P024. Regional differences in effect of TGF-beta1 and PDGF on the early onset of intestinal fibrosis
- P025. Reduced Butyricicoccus pulli-caecorum levels in mucosa of UC patients correlate with aberrant CLDN1 expression
- P026. Recreating the intestinal macrophage in vitro: a potential role for stromal factors
- P027. Proteomics analysis of serum and tissue proteins in patients with intestinal Behçet's disease by MALDI-TOF/TOF mass spectrometry
- P028. Protein kinase D1 mediates CREB activation and increased SOCS3 expression induced by PGE2 in colon epithelial cells
- P029. Protective effects of N-acetylcysteine on mitochondrial dysfunction, mucin-depleted crypts and epithelial apoptosis in dextran sulfate sodium-induced sub-acute colitis
- P030. Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation
- P031. Probiotic bacteria enhance antigen sampling and processing by dendritic cells in pediatric IBD
- P032. Pro-inflammatory cytokines induce the expression of TL1A/TNFSF15 in primary intestinal subepithelial myofibroblasts
- P033. Prevention of recurrent Clostridium difficile infection by neutralizing monoclonal antibodies in a hamster relapse model
- P034. Preliminary evidence for a role of the renin angiotensin system in intestinal fibrosis in Crohn's disease using angiotensin receptor immunohistochemistry
- P036. Polyfunctionality of human gut-homing CD4 T cells
- P037. Neutralization of CTLA-4 alleviates murine DSS-induced colitis through changing Th17-Treg profile
- P038. Neuropeptide S: effects on motility, contractility and inflammation in the rat and human gastrointestinal tract
- P039. Mucosal interleukin-33 levels in patients with moderate to severe ulcerative colitis before and after induction of endoscopic remission by infliximab
- P040. Mucosal T cell profiles in newly diagnosed, untreated inflammatory bowel disease patients
- P041. Modulation of inflammatory processes in mouse colitis models and gastrointestinal acute radiation syndrome with AVX-470m, an oral polyclonal anti-TNF antibody
- P042. Microbiota stability in vivo and in vitro
- P043. Microbial balances altered by restriction of dietary iron ameliorated immune-mediated colitis
- P044. MicroRNA expression in ileal inflammatory bowel disease correlates with disease behavior
- P045. Macrophage subtypes disrupt the epithelium via deregulated tight junctions and induction of apoptosis
- P046. Lymphocytic and collagenous colitis: two clinically similar entities but with a distinct immunological pattern
- P047. Involvement of PSGL1 and its ligands P-, E- and L-selectins in inflammatory bowel disease (IBD)
- P048. In vitro pancreas toxicity by azathioprine but not 6-mercaptopurine
- P049. Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept
- P050. Intraperitoneally injected mesenchymal stromal cells home significantly more often to the intestines in colitis mice compared to healthy controls
- P051. Interleukin 22 and interleukin 23R gene expression in Crohn's disease: preliminary results
- P052. Interleukin 10 (IL10) expression and distribution pattern in healthy and inflamed bowel. Relationship with steroid response in Crohn's disease (CD)
- P053. Interleukin-17A homodimer reduces pro-inflammatory cytokine production by inflammatory bowel disease mucosa cultured ex vivo
- P054. Interactions between neutrophil elastase and biologics in IBD
- P055. Integrated miRNA and gene expression profiling in patients with ulcerative colitis before and after infliximab treatment
- P056. Inhibition of matrix metalloproteinase-9 in intestinal inflammation by barbiturate–nitrate hybrids
- P057. Influence of colitis on ileal epithelial barrier and its environment in a new mouse model of ulcerative colitis
- P058. Increased expression of microRNA-122, microRNA-146a and microRNA-155 in intestinal mucosa of pediatric patients with Crohn's disease
- P059. Importance of NOD2 on mRNA and miRNA signatures in monocytes from Crohn's disease
- P060. Impact of intestinal inflammation on Foxp3+ regulatory T cells
- P061. Identification of the mesocolic mesothelium as a novel source of fibroblasts - implications for Crohn's disease
- P062. Identification of the XAF1 tumor suppressor as a transcription target of tumor necrosis factor-α – NF-κB signaling in human colon cancer cells
- P063. Identification of novel non-transcriptionally acting glucocorticoid receptor ligands that suppress T cell activation but lack adipogenic activity
- P064. Identification of inflammatory mediators in Crohn's disease patients who are unresponsive to anti-TNF therapy - A transcriptional analysis of intestinal mucosa
- P065. IL-33/ST2 axis modulates epithelial repair and gut mucosal wound healing in DSS-colitic mice
- P066. IL-17A has dual actions in the induction of colitis
- P067. IBD98E promotes mucosal wound healing through epithelial cell proliferation in DSS-induced colitis
- P068. Hyperbaric oxygen reduces hypoxia-inducible factor-1 alpha expression in experimental acute distal colitis
- P069. High autofluorescence of the colon tissues in children with ulcerative colitis
- P070. Healing of TNBS-induced colitis in the rat by peptide Hp(2-20)
- P071. G protein-coupled receptor 30 expression in inflammatory bowel disease patients
- P072. GLPG0634, the first selective JAK1 inhibitor, shows strong activity in the mouse DSS-colitis model
- P073. Fibrosis does not increase with disease duration in ulcerative colitis
- P074. Expression of CCL20 and its corresponding receptor CCR6 is located to epithelium and infiltrating cells in the mucosa of IBD patients
- P075. Epithelial Toll-like receptor 3-dependent synthesis of complement factor B and local complement activation in inflammatory bowel disease
- P076. Enhanced host adaptive response prerequisite to prevent relapse during maintenance therapy of IBD
- P077. Effects of IFN-γ priming on the functional characteristics of human bone marrow and adipose derived mesenchymal stem cells expanded in alternative xeno-free conditions
- P078. Effect of methanolic bark extracts of Chrysophyllum albidum on acetic acid-induced colitis in rats
- P079. Effect of enteral nutrition on dendritic cell phenotype in children with Crohn's disease
- P080. Effect of chondroitin sulphate on pro-inflammatory mediators and disease activity in patients with inflammatory bowel disease (IBD)
- P081. ER stress leads to epithelial to mesenchymal transition (EMT) in intestinal epithelial cells in a JNK- and Src-dependent manner
- P082. Divergent effects of gut bacteria altered in dysbiosis of inflammatory bowel disease on monocytes and macrophage polarisation
- P083. Divalent metal-ion transporter 1 deficiency contributes to the anemia in inflammatory bowel disease
- P084. Dissecting the role of PPARgamma in intestinal fibrosis: EMT-activator ZEB1 as new molecular target
- P085. Direct smooth muscle stimulatory effect of nitrergic inhibition by L-NMMA on the migrating motor complex modulated by muscarinic and 5-HT3 receptor blockade
- P086. Development and validation of ELISA to measure serum anti TNFa levels
- P087. Dendritic cell subsets in the maintenance of gut health and response to bioactives
- P088. Delineating lipopolysaccharide signalling pathway in ulcerative colitis through mucosal gene expression analysis
- P089. Decrease of peripheral leucocytes BIM protein expression in Crohn's disease
- P090. Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action
- P091. Controlling the balance of immunity in colitis: Investigating the roles of intestinal microbiota and dendritic cell migration
- P092. Co-administration of 5-aminosalicylic acid to 6-mercaptopurine reduces in vitro hepatotoxicity
- P093. Circulating microvesicles in Crohn's disease
- P094. CCL25/CCR9 interactions promote the induction and function of iNKT cells in oxazolone-induced colitis in mice
- P095. Antibodies anti-interferon-inducible protein 16 (FI16) are elevated in inflammatory bowel diseases
- P096. Analysis of the tryptophan metabolism and indoleamine 2,3-dioxygenase expression (IDO) in patients with inflammatory bowel disease before and after infliximab treatment
- P097. Analysis of the protease MT1-MMP and its substrates as biomarkers and therapeutic targets in inflammatory bowel disease
- P098. Action of hydrogen sulfide and NSAIDs on the activity of the NO-synthase system of the colon under the condition of stress
- P099. What is the real value of acid fast staining, PCR, and culture of endoscopically obtained tissue samples in diagnosis of gastrointestinal tuberculosis in patients with ileocecal inflammation? Comparative data from an Eastern European registry
- P100. Vitamin D in patients with Crohn's disease
- P101. Vitamin D deficiency in inflammatory bowel disease patients
- P102. Validation of a Portuguese version of the Inflammatory Bowel Disease Disability Score
- P103. Usefulness of fluorescence spectroscopy in the diagnosis of inflammatory bowel diseases
- P104. Usefulness of measurement of serum procalcitonin level in patients with inflammatory bowel diseases
- P105. Unusual presentation of tuberculosis as splenic nodules in a patient with Crohn's disease
- P107. Usefulness of a rapid test for fecal calprotectin as predictor of relapse in Crohn's disease patients under maintenance treatment with adalimumab
- P108. Towards patient-reported disease severity index in inflammatory bowel disease
- P109. Thiopurines and anti-TNFs after a diagnosis of cancer in patients with inflammatory bowel disease
- P110. The use of the Pediatric Ulcerative Colitis Activity Index (PUCAI) in adults with acute severe ulcerative colitis (ASC)
- P111. The usefulness of intestinal real time virtual sonography in patients with inflammatory bowel disease
- P112. The triggering role of Clostridium difficile infection in the relapse of IBD and the clinical utility of fecal calprotectin and matrix-metallo-proteinase-9 in case of Clostridium-induced relapse
- P113. The lived experience of attending a formal inflammatory bowel disease patient education programme. A phenomenological study
- P114. The influence of obesity on clinical course and behaviour of Crohn's disease
- P115. The influence of maternal IBD on childbirth and further development of children
- P116. The influence of appendectomy on the clinical course of ulcerative colitis: a hospital-based cohort study from Korea
- P117. The first description of primary sclerosing cholangitis (PSC) in association with collagenous colitis: was this predictable?
- P118. The diagnostic value of wireless capsule endoscopy in paediatric inflammatory bowel disease assessment: a tertiary centre experience
- P119. The diagnostic value of a new fecal marker matrix metalloprotease-9 in different types of inflammatory bowel diseases
- P120. The concentrations of calprotectin in stool samples vary during the day in patients with active ulcerative colitis
- P121. The clinical characteristics of Crohn's disease patients with free perforation in Korea
- P122. The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD
- P123. The use of faecal calprotectin in IBD and reducing unnecessary colonoscopy
- P124. The Modified Mayo Endoscopic Score (MMES): a new score for the assessment of extent and severity of endoscopic activity in ulcerative colitis (UC) patients
- P125. The effect of suppressing gastric acid secretion in Crohn's disease
- P126. The Belgian Registry of Pediatric Crohn's disease (BELCRO): growth status after 3 year follow up
- P127. The application of T-SPOT.TB in the differential diagnosis of Crohn's disease and intestinal tuberculosis
- P128. The “FUN”-concept. An innovative training model for intestinal ultrasound education
- P129. Terminal ileitis - Is it Crohn's disease?
- P130. The prevalence of iron deficiency and anemia in an IBD referral center in Serbia
- P131. Systematic analysis of factors associated with progression and regression of ulcerative colitis in the Swiss IBD Cohort study
- P132. Study of intestinal parasitic infections and risk factors among patients suffering from inflammatory bowel disease in Alexandria, Egypt
- P133. Small bowel stricture in Crohn's disease: The main factor for surgery indication?
- P134. Small bowel prestenotic dilatation is not related to severity degree of stricture and to surgical indication in Crohn's disease (CD) patients
- P135. Sleep disorders in inflammatory bowel disease: incidence and use of ambulatory polysomnography
- P136. Simple endoscopic score for Crohn's disease (SES-CD) predicts long-term prognosis in Crohn's disease patients with clinical remission
- P137. Sexual dysfunction in inflammatory bowel disease patients
- P138. Severe disease activity and cytomegalovirus colitis are associated with an increased risk of venous thromboembolism in patients with inflammatory bowel disease
- P139. Serum hepcidin levels predict intestinal iron absorption in IBD patients
- P140. Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn's disease
- P141. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity
- P142. Sensitivity of Lennard-Jones criteria in the diagnosis of Crohn's disease
- P143. Screening for latent tuberculosis in patients with inflammatory bowel diseases: impact of immunosuppressive drugs in the performance of an interferon-gamma release assay
- P144. Sarcopenia and osteopenia in patients with Crohn's disease
- P145. Small bowel capsule endoscopy for assessing the early postoperative recurrence of Crohn's disease: Correlation with the endoscopic score at 6 and 12 months in a prospective study
- P146. Role of fecal neutrophil gelatinase-associated lipocalin assessment in patients with inflammatory bowel disease
- P147. Role of endoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis
- P148. Role of interferon gamma release assay (IGRA) in differentiating gastrointestinal tuberculosis from Crohn's disease
- P149. Risk factors for post-colectomy complications in patients with ulcerative colitis
- P150. Responsiveness of endoscopic indices in the evaluation of ulcerative colitis
- P151. Recommendations for creating a high quality endoscopy report for inflammatory bowel disease patients: results from a RAND-appropriateness panel
- P152. Rising incidence and increasing severity of very early onset IBD in Ireland
- P153. Reactivation of cytomegalovirus in inflammatory bowel disease - a 10 year case series
- P154. Quality of life (QoL) and inflammatory bowel disease (IBD): The caregiver's perspective
- P155. Quality Improvement Tool: 3 year outcome
- P156. Pulmonary involvement in IBD patients and the effect of TNF-alpha inhibitors on pulmonary function
- P157. Proximal disease extension and related predicting factors in ulcerative proctitis
- P158. Prospective comparison of magnetic resonance imaging, rectal and perineal ultrasound and the surgical findings of complicated perianal Crohn's disease: a new kid on the block
- P159. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis may increase prevalence of primary sclerosing cholangitis with dominant stricture in a short period like 24 months
- P160. Prevalence of IBD among celiacs in our celiac centre
- P161. Presence of stenosing and penetrating lesions at MRI but not deep ulcers at endoscopy predicts surgery requirements in CD in the era of biologics
- P163. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antiTNF agents
- P164. Predictive factors of the course of Crohn's disease - can we treat in anticipation?
- P165. Predictive factors for chronic inflammatory bowel diseases in patients presenting with new onset diarrhea
- P166. Predictive factors for anatomic extent of lesions in patients affected by ulcerative colitis
- P167. Prediction of clinical outcome in Crohn's disease by using confocal laser endomicroscopy: a prospective, observational, follow-up study
- P168. Predicting outcome in acute ulcerative colitis: Comparison of the Travis and Ho scores using UK IBD Audit data
- P169. Plasma biomarkers of endothelial dysfunction: monocyte chemoattractant protein 1 (MCP 1) and soluble CD40 ligand (CD40L) in patients with inflammatory bowel diseases
- P170. Planar radiolabelled white cell scintigraphy and Technetium-99m-HMPAO labeled leukocyte single photon emission computed tomography (SPECT) for assessing endoscopic remission in ulcerative colitis
- P171. Physiological intermolecular modification spectroscopy (PIMS) for the prediction of response to anti-TNF therapy in patients with inflammatory bowel diseases
- P172. Photodynamic surveillance of colitis-associated dysplasia in patients with ulcerative colitis and in mouse model, by visualization following oral 5-amino-levulinic acid sensitization
- P173. Peroxisome proliferator-activated receptors family is involved in the response to treatment and clinical course in patients with ulcerative colitis
- P174. Pediatric ulcerative colitis; presenting features, therapeutic approach and disease course
- P175. Patients' perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis
- P176. Patient reported outcome measures derived from the Crohn's Disease Activity Index: Correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds
- P177. Phenotypic and therapeutic differences in Crohn's disease depending on age at diagnosis
- P178. Outcomes of pregnancies among women with inflammatory bowel disease: results from a single-center cohort
- P179. Outcome of pouch surgery for ulcerative colitis in 124 Egyptian patients
- P180. Non-invasive assessment of cardiovascular risk in young patients with inflammatory bowel disease (IBD) compared with healthy controls (HC)
- P181. Natural history of non-severe IBD at diagnosis
- P182. Multiparametric evaluation of Crohn's disease: possible role of intestinal healing beyond mucosal healing
- P183. Multidisciplinary approach in IBD patients with arthralgias: usefulness of a combined rheumatologic and gastroenterologic assessment in a prospective study
- P184. Mucosal healing does not correspond to histological healing in ulcerative colitis
- P185. Mucin 16 (MUC16) and mucin 20 (MUC20) over-expression in colonic mucosa is associated with histological remission in patients with ulcerative colitis
- P186. Mitochondrial activity of B-lymphocytes in children with IBD receiving infliximab
- P187. MRI T2 relaxometry to image fibrosis in patients with Crohn's disease
- P188. MR-enterography in Crohn's disease: DWI-ADC values in normal and affected bowel loops
- P189. Lung-free lymphomatoid granulomatosis and Crohn's disease: An unknown asocciation
- P190. Low muscle mass in inflammatory bowel disease (IBD): common and predictive of functional sarcopenia and osteopenia
- P191. Low-volume bowel preparation containing picosulfate/magnesium citrate in patients aged 65 years and older compared with younger patients: safety, tolerability, and efficacy
- P192. Long-term outcome of endoscopic balloon dilatation in Crohn's stenosis is not associated to steroid intrastricture injection and to use of larger balloon
- P193. Long-term incidence and characteristics of intestinal failure in Crohn's disease: A Japanese multicentre study
- P194. Lithogenic factors in inflammatory bowel disease
- P195. Leukocyte scintigraphy as a tool to measure inflammatory load in ulcerative colitis
- P196. Laboratory assessment of inflammation activity in pediatric inflammatory bowel disease
- P197. Is the tuberculin skin test alone accurate in moderate-to-severe BCG vaccinated patients with inflammatory bowel disease to test for latent tuberculosis?
- P198. Is terminal ileal inflammation predictive of small bowel Crohn's disease?
- P199. Is contrast-enhanced ultrasound (CE-US) superior to conventional ultrasonography (cUS) for the assessment of small bowel Crohn's disease inflammatory activity, as graded by magnetic resonance enterography (MRI)?
- P200. Is anemia a prognostic factor for disease behavior in IBD? - A Romanian National Register based evidence study
- P201. Is depression associated with more emergency visits in inflammatory bowel disease?
- P202. Ipilimumab colitis: a GETAID multicentric study
- P203. Inflammatory bowel disease and compliance with the Mediterranean diet
- P204. Inflammatory joint- and bowel diseases - a clinical proteomics study seeking to identify the underlying biological triggers
- P205. Indicators of inadequate response to biologic therapies in patients with Crohn's disease from real-world practice settings
- P206. Indicators of inadequate response to anti-tumour necrosis factor therapies in patients with ulcerative colitis from real-world practice settings
- P207. Indeterminate and inconclusive results are common when using interferon gamma release assay as screening for TB in patients with IBD
- P208. Ileal wall thickness detected by MSCTE predicts the disease severity of Crohn's disease
- P209. Influence of anxiety and depression in the clinical course of inflammatory bowel disease patients
- P210. IBD and HIV: Does CD4 count remission hypothesis count?
- P211. IBD-Unclassified in childhood and adolescence; a complicated diagnosis
- P212. How to ameliorate histology accuracy in IBD diagnosis: role for a better interaction between clinicians and pathologists?
- P213. High prevalence of subclinical ultrasonographic synovitis in patients with inflammatory bowel disease
- P214. Health-related quality of life among patients with primary sclerosing cholangitis
- P215. Growth pattern and growth failure in paediatric Crohn's disease are related to inflammatory status but not to duration of steroid therapy
- P216. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy
- P217. Family functioning and health-related quality of life in children with inflammatory bowel disease
- P218. Faecal calprotectin testing reduces need for paediatric colonoscopy
- P219. Faecal calprotectin is an accurate predictor of endoscopic and histological disease activity in IBD
- P220. Faecal calprotectin and ileal Crohn's disease: correlation with a small bowel MRI score for disease activity
- P221. Faecal calprotectin concentrations in Crohn's patients with ileal disease location: correlations with disease activity as seen by MRI enterography
- P222. Fecal calprotectin as a marker of severity of mucosal involvement in children with inflammatory bowel disease
- P223. Faecal calprotectin testing in primary and secondary care - Are the current manufacturer's cut-off values clinically useful?
- P224. Exhaled pentane may identify disease activity in patients with inflammatory bowel diseases
- P225. Evaluation of the relationship between serum ghrelin, C-reactive protein and interleukin-6 levels and disease activity in inflammatory bowel diseases
- P226. Evaluation of intestinal permeability on the basis of zonulin levels, in children with inflammatory bowel disease
- P227. Evaluation of a method to detect cytomegalovirus-DNA in intestinal fluid samples of patients with ulcerative colitis
- P228. Evaluation of the correlation between serum levels of hepcidin and disease activity in inflammatory bowel diseases
- P229. Environmental and clinical risk factors for severe Crohn's disease
- P230. Endoscopy in IBD women is safe in each trimester of pregnancy
- P231. Early onset inflammatory bowel disease: phenotype and burden of disease. Experience at Cambridge University Hospitals - United Kingdom
- P232. Evaluation of the use of fecal calprotectin as a diagnostic aid for IBD in an Irish population
- P233. Early measurement of fecal calprotectin after intestinal resection is useful to predict postoperative recurrence in patients with Crohn's disease
- P234. Double balloon endoscopy and Crohn's disease: Does it still work?
- P235. Does liver transplantation affect the risk for colorectal neoplasia in PSC-IBD patients?
- P236. Disease severity after 3 years of treating newly diagnosed pediatric Crohn's disease patients (the BELCRO cohort)
- P237. Differential diagnosis between intestinal tuberculosis and Crohn's disease - A prospective multicenter study from China
- P238. Diagnostic value of serum adenosine deaminase levels in patients with inflammatory bowel diseases
- P239. Diagnostic delay in pediatric Crohn's disease patients is longer than in pediatric ulcerative colitis patients
- P240. Diagnosis of iron deficiency in inflammatory bowel diseases by transferrin receptor-ferritin index
- P241. Development of a novel prediction model for natural course in Crohn's disease: A Korean multicenter, retrospective cohort study
- P242. Development and psychometric testing of an inflammatory bowel disease fatigue (IBD-F) patient self-assessment scale
- P243. Development and initial validation of a unique score for in vivo differentiation of ulcerative colitis and Crohn's disease featuring confocal laser endomicroscopy
- P244. Development and initial validation of a new assessment tool for faecal incontinence in inflammatory bowel disease: the International Consultation on Incontinence Questionnaire: Inflammatory Bowel Disease (ICIQ-IBD)
- P245. Determining patient & disease related risk factors for the development of clinical recurrence following ileocolic resection for Crohn's disease within a tertiary IBD unit
- P246. Disease control and unmet needs among moderate to severe ulcerative colitis patients treated with conventional therapies in Europe: The UC CARES (Ulcerative Colitis condition, attitude, resources and educational study) study
- P247. Development of a new tool to assess Crohn's disease magnetic resonance inflammation severity
- P248. Cryptogenic multifocal ulcerating stenosing enteritis (CMUSE): to be differentiated from Crohn's disease
- P249. Cross sectional imaging techniques data compared to per-operative data in patients with Crohn's disease
- P250. Correlation of faecal calprotectin levels with Crohn's disease activity scores using two different immunoassays
- P251. Correlation of FDG PET scanning with clinical and laboratory markers of activity in patients with Crohn's disease
- P252. Correlation between severity of endoscopic lesions and clinical activity in a cohort of Crohn's disease patients followed up for 5 years after ileo-colonic resection
- P253. Conventional and contrast-enhanced ultrasound (CEUS) in the evaluation of Crohn's disease activity
- P254. Contrast enhanced ultrasound as a point-of-care technique in complicated Crohn's disease patients
- P255. Computed virtual chromoendoscopy with FICE in the definition of raised dysplastic lesions and pseudopolyps in long-standing ulcerative colitis: a preliminary, prospective, study towards a new classification
- P256. Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel iSCAN endoscopic and refined histological gradings
- P257. Comparison of first recurrence rates between pediatric Crohn's disease and young adult onset Crohn's disease
- P258. Comparing MR enterocolonography to enteroscopy in Crohn's disease, especially focusing on small intestinal findings
- P259. Comparative retrospective assessment of prospectively recorded endoscopic and histological findings between CD and GI-TB; the first Eastern European registry data
- P260. Clinical usefulness of serum IL-32 in Crohn's disease
- P261. Clinical usefulness of fecal calprotectin measurement in predicting intestinal involvement of Behçet's disease: preliminary results
- P262. Clinical outcome of perianal Crohn's disease: Natural history and impact of medical and surgical strategies over time
- P263. Clinical impact of magnifying chromoendoscopy on assessment of mucosal healing and prediction of disease relapse in quiescent ulcerative colitis
- P264. Clinical features and prognosis of fistulizing perianal Crohn's disease in Korea
- P265. Clinical characteristics and oncologic outcomes in patients with colorectal cancer complicating ulcerative colitis: a single-institution experience
- P266. Chronic inflammatory bowel disorders diagnosed by screening colonoscopy for health check-up
- P267. Chronic viral hepatitis in Asian patients with inflammatory bowel disease
- P268. Chemerin, visfatin and vaspin levels in relation to fat mass and bone mineral density in IBD
- P269. Characteristic endoscopic findings and risk factors for cytomegalovirus colitis in patients with active ulcerative colitis
- P270. Capsule endoscopy (CE) is superior to magnetic resonance enterography (MRE) for the assessment of small bowel lesions in Crohn's disease (CD) patients: a comparative trial
- P271. Correlations between MR findings and disease activity in Crohn's disease
- P272. Can fecal calprotectin (FC) predict activity in the MR-enterography in small bowel Crohn's disease (CD)?
- P273. Bone health management in inflammatory bowel disease patients amongst Australian gastroenterologists
- P274. Body composition measurement among IBD patients
- P275. Bile acid malabsorption involvement in Crohn's disease symptoms. Its relationship with ROME III criteria
- P276. Association between serum 25-hydroxy vitamin D concentration and inflammatory bowel disease characteristics in North-Eastern Romania
- P277. Assessment of the performance of the colonic PillCam PCC2 in Crohn's patients
- P278. Aspects that determine patient satisfaction in the management of mild to moderate ulcerative colitis: a Delphi study of patients and physicians
- P279. A report on the prevalence and reactivation rate of hepatitis B virus in patients with inflammatory bowel disease in Japan
- P280. Anti glycoprotein-2 antibody in pediatric inflammatory bowel disease and celiac disease: prevalence, diagnostic value and variation at follow-up
- P281. Anti-GP2 antibodies in children with Crohn's disease receiving infliximab
- P282. A new patient reported outcome measure: The short Crohn's and Colitis Questionnaire (CCQ) for patients with inflammatory bowel disease
- P283. Anemia in ulcerative colitis patients - a prospective monocentric study in North-Eastern Romania
- P284. Agreement of central readers in the evaluation of histopathological disease activity in ulcerative colitis
- P285. Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score
- P286. Age at diagnosis and clinical characteristics of Crohn's disease in Korea: a KASID multicenter study
- P287. Accuracy of fecal calprotectin in the prediction of endoscopic activity in inflammatory bowel disease patients
- P288. Accuracy of small intestine contrast ultrasonography compared to magnetic resonance enterography in characterizing lesions in patients with Crohn's disease
- P289. Anaemia and iron deficiency in pediatric inflammatory bowel disease
- P290. Diagnosing microscopic colitis - is colonoscopy necessary?
- P291. “IBD MOM”: report of a new concept in the treatment of IBD in pregnancy
- P292. Smart phones for inflammatory bowel disease
- P293. eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis
- P294. Yield of colon surveillance and clinical outcome after faecal diversion in patients with Crohn's disease
- P295. What is our success on complex perianal fistula healing in the clinic? From antibiotic to combined anti-TNF based treatment, ending with or without ileostomy
- P296. What happens to patients with paediatric onset inflammatory bowel disease (IBD) after transition to adult care and what is their view of the process?
- P297. What do healthcare professionals know about fatigue in patients with IBD and how do they manage it?
- P298. Vitamin D status and inflammatory bowel disease - the role in disease activity and quality of life
- P299. Vagus nerve stimulation in Crohn's disease
- P300. Vaccination routines during anti-TNF treatment in IBD: Do patients adhere to ECCO's guidelines?
- P301. Utility of faecal lactoferrin measurement in ulcerative colitis patients with granulocyte and monocyte adsorptive apheresis
- P302. Utility of “trough levels” determination and anti-infliximab antibodies in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters (PK) through population pharmacokinetic model
- P303. Ulcerative colitis (UC) in the elderly - Moderate at onset but then a milder course? An IG-IBD study
- P304. Two year study of high and low dose oral vitamin D replacement therapy in adult inflammatory bowel disease
- P305. Tuberculosis infection in inflammatory bowel disease patients after anti-TNF therapy in a high tuberculosis prevalence rate area
- P306. Tryptophan deficiency in Crohn's disease
- P307. Treatment preferences of patients with Crohn's disease candidates for anti-TNF treatment. A conjoint analysis (IMPLICA study)
- P308. Treatment of corticosteroid naive children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications
- P309. Transition experience from inpatient to ambulatory IBD care: Results of a pilot study
- P310. Toxicity of thiopurines in patients with inflammatory bowel disease: Frequency and risk factors
- P311. Thiopurine metabolite monitoring and allopurinol combination therapy: current utilisation and influence on Australian gastroenterology IBD practice
- P312. Thiopurine metabolite testing in inflammatory bowel disease
- P313. The use of sirolimus for refractory inflammatory bowel disease: A single centre experience
- P314. The type of iron deficiency anaemia, but not the underlying disease, predicts intestinal iron absorption in IBD patients
- P315. The role of FGF19 in the assessment of diarrhoea and disease activity in non-ileal resected Crohn's disease
- P316. The risk of preoperative anti-TNF-α treatment on early postoperative complications in patients with Crohn's disease
- P317. The rate of drug usage and side-effects in inflammatory bowel disease
- P318. Therapeutic depletion of myeloid lineage leucocytes in patients with ulcerative colitis: Demographic features of responders and non-responders to this non-pharmacological treatment option
- P319. The prevalence and clinical characteristics of refractory Crohn's disease in South China
- P320. The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry
- P321. The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis
- P322. The effects of anti TNF therapy on growth in Scottish children with IBD
- P323. The effectiveness of adalimumab maintenance treatment for Crohn's disease and related prognostic factors: a Japanese single-center study
- P324. The clinical comparative demographic features between inpatient and outpatient of IBD
- P325. The budgetary impact of 2 g mesalazine for the treatment of mild to moderate ulcerative colitis
- P326. The association between inflammatory bowel disease (IBD) and parity
- P327. The value of social media in inflammatory bowel diseases
- P328. The use of IVIG in IBD patients with contraindications or who are unresponsive to conventional treatment for inflammatory bowel disease
- P330. The impact of peri-operative administration of infliximab on the healing process of intestinal anastomosis: A rat experimental study
- P331. The elimination of cytomegalovirus in patients with ulcerative colitis without antiviral therapy
- P332. The efficacy of tonsil-derived mesenchymal stem cell in acute murine colitis model
- P333. The development of coordinated care pathways and feasibility testing in inflammatory bowel disease management
- P334. Thalidomide associated with anti-TNF-α therapy in Crohn's disease patients who lost response to anti-TNF-α: a case series
- P335. Two-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
- P336. TNF alpha inhibitor use in pregnancy: experience in a European cohort
- P337. TNF-alpha as induction therapy for Crohn's disease: a comparison of adalimumab and infliximab - a prospective observational study in Germany
- P338. Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence
- P339. Surgical treatment of female genital fistula in Crohn's disease
- P340. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease - the McGill experience
- P341. Steroids may reduce the benefit of exclusive enteral feeding in paediatric Crohn's disease
- P342. Splitting the normal daily dose of thioguanine may be efficacious treatment for IBD and avoid hepatic toxicity
- P343. Skewed thiopurine metabolism leads to therapeutic failure in the majority of thiopurine using IBD patients
- P344. Short and medium term efficacy of adalimumab in ulcerative colitis - a multicentre, prospective observational study
- P345. Short- and long-term efficacy of granulocytapheresis in patients with active steroid-dependent ulcerative colitis refractory or intolerant to thiopurines. A retrospective single-centre study
- P346. Short term dose tailoring of anti TNF-α therapy delivers useful clinical efficacy in Crohn's disease patients with secondary loss of response
- P347. Severe scalp and skin involvement in Crohn's disease patients under treatment with anti-tumor necrosis factor alpha
- P348. Serum infliximab levels and early mucosal healing in Crohn's disease
- P349. Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?
- P350. Serum CRP is a better early marker for response to infliximab induction therapy than fecal calprotectin in patients with moderate to severe ulcerative colitis
- P351. Screening for opportunistic infection prior to initiating immunomodulator therapy in IBD patients - Practice in the North East of England
- P352. Screening for melanoma and non melanoma skin cancer in IBD patients before treatment with thiopurines and anti-TNFs: A prospective cohort study
- P353. Screening for latent tuberculosis is effective but does not fully protect against tuberculosis reactivation during anti-TNF treatment in areas with high background incidence of tuberculosis
- P354. Satisfaction and concerns about anti-TNF alpha therapy in Crohn's disease - the patient's perspective in a Portuguese population
- P355. Safety and efficacy of restorative proctocolectomy in the elderly. A European, prospective, multicenter, S-ECCO study
- P356. Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist
- P357. Role of THD in patients affected by Crohn's disease and haemorrhoidal disease: a preliminary study
- P358. Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years (GETAID survey)
- P359. Risk factors for pouchitis after laparoscopic ileal-pouch-anal anastomosis in patients with ulcerative colitis
- P360. Risk factors for complications after laparoscopic ileal-pouch-anal anastomosis in patients with ulcerative colitis
- P361. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy
- P362. Retrospective comparison of the efficacy of anti-TNF agents in isolation or combined with azathioprine in prevention of early postoperative endoscopic recurrence in Crohn's disease from the MULTIPER database
- P363. Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re-induction regimens
- P364. Resected fibrostenotic intestine from Crohn's disease patients express significant TNF in proliferative fibroblasts and in extracellular matrix
- P365. Remission status and maintenance therapy outcomes in patients with mild-to-moderate ulcerative colitis (UC): Results from the MOMENTUM study
- P366. Relevance of chromogranin A according to disease activity and medical treatment in IBD patients
- P367. Rate of and response to dose escalation in paediatric patients with Crohn's disease from IMAgINE 1
- P368. Rare skin disorders in IBD patients treated with anti-TNFs
- P369. Rapid infusion, high dose ferric carboxymaltose in the treatment of iron deficiency in paediatric inflammatory bowel disease - a single centre experience
- P370. Prospective withdrawal trial of azathioprine (AZA) in ulcerative colitis (UC)
- P371. Prospective study of prevalence and incidence of vertebral fractures in long-term anti-TNF alpha maintenance therapy treatment for inflammatory bowel disease
- P372. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients
- P373. Profiles of dental caries and periodontal disease in individuals with or without inflammatory bowel disease (IBD)
- P374. Probiotics can extend remission of ulcerative colitis
- P375. Primary response to infliximab therapy in IBD patients is reflected in the normalisation of the haemostatic profile
- P376. Prevalence of surgical treatment of Crohn's disease according to period of diagnosis: preliminary data of a 30-year experience in a single centre
- P377. Pregnancy outcome and counselling of anti-TNF-alpha treated IBD women: an ongoing international multicentre study
- P378. Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions
- P379. Predictors of response to medical treatment in Crohn's disease patients with intestinal obstruction
- P380. Predictors of clinical response to immunomodulators in moderate to severe Crohn's disease
- P381. Predictors and frequency of anti-TNF dose escalation in patients with inflammatory bowel disease
- P382. Predictor of effect of oral tacrolimus on refractory ulcerative colitis
- P383. Predictive factors of early infliximab infusion reactions in inflammatory bowel disease
- P384. Predictive factors of response to prolonged intravenous corticosteroids in patients with acute severe ulcerative colitis
- P385. Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease
- P386. Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease
- P387. Persistence of antibodies to infliximab for more than two months strongly predicts loss of response to infliximab in inflammatory bowel diseases
- P388. Perifistular application of adipose-derived mesenchymal stem cells - experimental study
- P389. Patients' self-assessment of their knowledge about ulcerative colitis indicates level of adherence
- P390. Patient perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?
- P391. Patient co-payments in Latvia and Estonia and the use of azathioprine
- P392. Patient knowledge of reproductive issues in inflammatory bowel disease is only one of many factors that affect decisions regarding family planning
- P393. Patient-reported symptom measures differ in their association with mucosal healing in adults with moderately to severely active ulcerative colitis: Results from ULTRA 1 and 2
- P394. Pooled clinical trial analysis of MMX mesalazine safety: Focus on 4.8 g/d dose long-term exposure
- P395. Perianal Crohn's disease - Experience of a tertiary referral center
- P396. Outcomes of surgical treatment of entero-urinary fistulas in Crohn's disease
- P397. Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease
- P398. Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center
- P399. Oral butyrate plus inulin improve serum metabolomic profile and gut microbiota composition in ulcerative colitis and celiac disease
- P400. Opportunistic infections in anti-TNF treated IBD patients: analysis from three tertiary centers in Romania
- P401. Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: Single centre preliminary data
- P402. Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up
- P403. Normalisation of faecal calprotectin is an absolute marker of mucosal healing and predicts long-term remission in ulcerative colitis (UC)
- P404. Normal CRP remission as an outcome parameter in pediatric Crohn's disease: Evaluation of the Porto IBD Group “Growth Relapse and Outcomes With Therapy” (GROWTH CD) cohort study
- P405. Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued?
- P406. Mucosal healing in children with Crohn's disease on long term maintenance treatment
- P407. Mucosal healing during the clinical remission in patients with ulcerative colitis
- P408. Motivational interviewing in inflammatory bowel disease patients: a useful tool during outpatient counselling
- P409. More targeted evaluation of nutrition in inflammatory bowel disease (IBD) reveals opportunities to optimise care: body mass index, body composition and iron deficiency
- P410. Microbiota profiling in PSC and control patients: A pilot study
- P411. Meta-analysis of the efficacy of a second-line anti-TNF in inflammatory bowel disease patients with failure to a previous anti-TNF treatment
- P412. Medication adherence in patients with active Crohn's disease: results from a large Italian multicenter survey
- P413. Management of ulcerative colitis patients in clinical practice: results of a nationwide survey (CROSSOVER) conducted in Spain
- P414. Management of gastrointestinal Behçet's disease refractory to conventional treatment
- P415. MRI assessment of body composition in paediatric Crohn's disease; intra-abdominal adipose tissue association with disease severity
- P416. MDR1 C3435 gene polymorphism and several clinical risk factors associated with glucocorticoid dependence and resistance in inflammatory bowel disease
- P417. Managing pediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN Guidelines: Efficacy of infliximab as a rescue therapy
- P418. Low dose naltrexone in therapy resistant IBD, a case series
- P419. Low dose azathioprine and allopurinol in azathioprine intolerant patients: is it tolerated and is it effective in IBD?
- P420. Low dose azathioprine and allopurinol co-therapy: is it safe to use without metabolite monitoring?
- P421. Long term results of infliximab treatment of fistulas in patients with Crohn's disease in Arctic Norway
- P422. Long term outcomes from leucocytapheresis in ulcerative colitis: A retrospective case series from a large UK centre
- P423. Long term outcome for sequential rescue treatments in steroid refractory ulcerative colitis - a real life experience
- P424. Long term efficacy of granulocyte-monocyte-apheresis in ulcerative colitis. The Italian Registry of Therapeutic Apheresis
- P425. Long term effects of anti-TNF-therapy on bone mass in IBD, a retrospective cohort study
- P426. Long-term safety of adalimumab in paediatric patients with Crohn's disease
- P427. Long-term outcomes of ulcerative colitis patients on thiopurine maintenance treatment
- P428. Long-term clinical outcomes of Korean patients with Crohn's disease
- P429. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study
- P430. Long-term outcome of Crohn's disease patients treated with infliximab
- P431. Long-term efficacy of maintenance therapy with thiopurines in Crohn's disease
- P432. Long term follow-up results of 14 patients with dominant stricture with PSC in IBD
- P433. Is e-Health, web-based monitoring and treatment, useful for children and adolescents with inflammatory bowel disease? - a paediatric clinical trial
- P434. Iron deficiency anemia in inflammatory bowel disease: are we treating our patients efficiently?
- P435. Intravenous iron need to maintain stable haemoglobin - an open-label, 1 year extension study of iron isomaltoside 1000 in subjects with inflammatory bowel disease
- P436. Intravenous cyclophosphamide combined with thalidomide has a promising effect in refractory Crohn's disease
- P437. Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): Efficacy, safety and health-related quality of life (HRQOL)
- P438. Intolerance to IBD treatment in over 1,800 patients in the Oxford IBD Cohort
- P439. In patients with Crohn's disease, timing of switching from infliximab to adalimumab affects prognosis
- P440. Influence of induction therapy with infliximab on histological changes in children with ulcerative colitis - preliminary data
- P441. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in IBD patients
- P442. Infliximab versus combination infliximab and immunosuppressant therapy for patients with active ulcerative colitis: a meta-analysis
- P443. Infliximab use during pregnancy in Crohn's disease
- P444. Infliximab trough levels and antibodies: relationship with infusion reaction, immunomodulators and biological parameters
- P445. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy
- P446. Infliximab is an effective induction therapy in children with perianal fistulizing Crohn's disease
- P447. Infliximab in the treatment of moderate-to-severe ulcerative colitis: Results of a large multicenter Italian survey
- P448. Inflammatory and cancerous skin lesions in inflammatory bowel disease patients treated with anti-TNF therapy
- P449. Inflammatory bowel disease patients' partner - how important is their support?
- P450. Inflammatory bowel disease patients' satisfaction with hospital care - a novel evaluation model
- P451. Induction of remission in Crohn's disease in children and young adults using a Crohn's Disease Exclusion Diet (CDED)
- P452. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program
- P453. Incidence of side effects and unspecific infections in the therapy with immunosuppressive therapeutics: a prospective observational study in 158 IBD patients
- P454. In IBD outpatients knowledge of fecal calprotectin and infliximab trough levels significantly enhances infliximab dose escalation decision making
- P455. Improvement of ulcerative-colitis-associated microbiota dysbiosis after treatment with mesalazine-MMX (Mezavant®) using mucosal Faecalobacterium prausnitzii/Escherichia coli index as a marker
- P456. Impact of short-term and long-term daily therapy with MMX mesalazine on work-related outcomes in patients with mild-to-moderate ulcerative colitis
- P457. Impact of medical therapies on the natural history in ulcerative colitis. An 8-year follow-up of a cohort study from a tertiary center
- P458. Impact of concomitant immunosuppressant use on adalimumab efficacy in children with moderately to severely active Crohn's disease: Results from IMAgINE 1
- P459. Impact of inflammatory bowel disease on patients' daily life: An online Korean Association for the Study of Intestinal Disease (KASID) survey
- P460. Immune responses and safety of intramuscular or intradermal trivalent influenza vaccines in patients with inflammatory bowel disease: a randomized controlled trial
- P461. Influence of melatonin on the course of ulcerative colitis
- P462. Influence of immunosuppressant treatment on the development and progression of neoplasms in patients with inflammatory bowel disease
- P463. Infliximab use in ulcerative colitis from 2003 to 2013: Clinical practice, safety and efficacy
- P464. Infliximab optimisation in ulcerative colitis: Intensificated and deintensificated patients clinical outcome
- P465. IL-4 in pathogenesis of systematic manifestations of ulcerative colitis
- P466. Hypogonadal patients with Crohn's disease benefit from treatment with testosterone - data from an ongoing, long-term, observational registry study
- P467. How often do we discontinue maintenance infliximab due to clinical remission in Crohn's disease?
- P468. Hospitalization rate before and after anti-TNF therapy, results from two referral centers
- P469. Higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence
- P470. High infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance IFX therapy
- P471. Hematopoietic stem cell transplantation in refractory Crohn's disease: Feasibility and toxicity
- P472. Head-to-head comparison of 5 fecal markers to predict response to induction and maintenance therapy with infliximab in ulcerative colitis patients; a prospective study
- P473. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab
- P474. Gut microbiota in patients with inflammatory bowel disease and irritable bowel syndrome before and after 6 weeks of low FODMAP diet
- P475. Granulocyte and Monocyte Apheresis (GMA) - Adacolumn® in mild to moderate ulcerative colitis patients with steroid resistance or dependence and azathioprine intolerance or resistance: a prospective multicenter study (preliminary data)
- P476. Gender specific differences in quality of life in Danish paediatric patients with inflammatory bowel disease
- P477. Fecal calprotectin reflects mucosal healing in ulcerative colitis
- P478. Feasibility and utility of a lactoferrin twice weekly monitoring in patients with ulcerative colitis
- P479. Feasibility and utility of a web-based self-reporting symptoms diary of Crohn's disease
- P480. Fast, safe and effective treatment of iron deficiency (ID) of different aetiologies using iron isomaltoside 1000 - experience from clinical practice
- P481. Failure of infliximab treatment in Crohn's disease is associated with the presence of fibrosis
- P482. Faecal calprotectin can be used to monitor response to therapy in anti-TNF treated patients with Crohn's disease
- P483. Faecal calprotectin exhibits diurnal variation in inflammatory bowel disease patients but is not affected by time of day
- P484. Functional cellular based assay reveals neutralising anti-drug antibodies in IBD patients treated with maintenance adalimumab
- P485. Fecal lactoferrin, calprotectin, PMN-elastase, CRP and white blood count as indicator for clinical course of disease and mucosal healing in patients with ulcerative colitis: A prospective 12-month monitoring study
- P486. Factors influencing the time to and outcome of dose escalation of adalimumab in Crohn's disease patients who achieved steroid-free remission on adalimumab
- P487. Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing
- P488. Exposure–response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease
- P489. Exposure–response relationship during vedolizumab induction therapy in adults with ulcerative colitis
- P490. Evolution of the first-line biologic treatment and cost derived from biologic therapy from year 2000: Results of the Biologic Therapies Unit (BTU) at Hospital Universitario de La Princesa
- P491. Epidemiology and clinical features of bloodstream infections in patients with inflammatory bowel disease
- P492. Endoscopic follow up of patients with IBD and biological treatment: achievement and persistence of mucosal healing in patients with clinical remission
- P493. Endoscopic balloon dilatation in patients with Crohn's disease (CD): Long-term outcome and patient satisfaction
- P494. Elderly patients with inflammatory bowel disease under anti-TNF therapy: efficacy and safety
- P495. Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab
- P496. Efficacy of infliximab therapy in acute and sub-acute ulcerative colitis
- P497. Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6
- P498. Efficacy of anti TNF-treatment for fistulizing Crohn's disease
- P499. Efficacy of adalimumab for induction and maintenance of remission in intestinal Behçet's disease
- P500. Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active UC with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 12 weeks
- P501. Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders
- P502. Effect of immunosuppressive treatment in the efficacy of Hepatitis B vaccine in patients with inflammatory bowel disease
- P504. Effectiveness and adverse events of azathioprine in inflammatory bowel disease: 9-year follow-up study
- P505. ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies - Preliminary data
- P506. Efficacy and safety of two bowel preparations for colonoscopy in IBD patients
- P507. EBV serology status and azathioprine-associated complications: a single centre study
- P508. Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice
- P509. Do you overlook the Clostridium difficile infection after TB medication?
- P510. Do patients enrolled in pivotal trials represent all inflammatory bowel disease population? EFIFECT study
- P511. Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database
- P512. Disseminated granuloma annulare associated with Crohn's disease: a rare extraintestinal manifestation
- P513. Disparity between infliximab trough level and infliximab associated adverse events
- P514. Disease-specific health-related quality of life in adult patients with mild to moderate ulcerative colitis receiving short-term and long-term daily treatment with MMX mesalazine
- P515. Disease-related knowledge in inflammatory bowel disease
- P516. Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody study
- P517. Discrepancy between efficiency and effectiveness of biological therapy in inflammatory bowel disease: EFIFECT study
- P518. Discordance among patients and parents regarding the perceived source of symptom relapse in young inflammatory bowel disease patients
- P519. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocecal resection for Crohn's disease: results from the MULTIPER database
- P520. Demographic features and long-term follow up outcome comparisons between patients with solo inflammatory bowel disease vs. inflammatory bowel disease and concomitant ankylosing spondylitis
- P521. Cytomegalovirus infection and response to influenza vaccination in inflammatory bowel disease patients on anti-TNF therapy
- P522. Cytapheresis as remission induction therapy in 154 ulcerative colitis patients: A five year experience
- P523. Cyclosporin rescue therapy is as effective as infliximab at preventing colectomy
- P524. Crohn's disease localization does not contribute to response for induction therapy with infliximab in children
- P525. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience
- P526. Correlation of 6-TGN levels with clinical remission in patients with ulcerative colitis treated with azathioprine
- P527. Correlation between the Crohn's Disease Activity Index and a web-based self-reporting symptoms diary of Crohn's disease
- P528. Complications of IBD in the anti-TNF era: reason for optimism?
- P529. Compassionate access use of anti-TNF therapy in ulcerative colitis in six Australian IBD centres has been beneficial to patient outcomes
- P530. Comparison between liposomial iron and ferrous sulfate in patients with iron deficiency anemia and inflammatory bowel disease. A pilot controlled study
- P531. Comparative assessment of the safety of cell and standard anti-inflammatory therapy of ulcerative colitis
- P532. Colon cancer in IBD patients treated or untreated with anti-TNFs: A retrospective matched-pair study in a 13 years follow up
- P533. Colectomy rate and mortality in hospitalized severe ulcerative colitis patients over the past 40 years
- P534. Co-prescription of allopurinol can overcome adverse events of thiopurine therapy and lead to remission in inflammatory bowel disease patients
- P535. Clinical predictors of immunomodulation and phenotype progression in Crohn's disease
- P536. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease
- P537. Clinical factors of anastomotic recurrence revealed in patients with Crohn's disease at double-balloon enteroscopy
- P538. Clinical and endoscopic recurrence after surgical resection in patients with Crohn's disease
- P539. Clinical response and mucosal healing after infliximab rescue therapy for patients with severe ulcerative colitis refractory to systemic corticosteroids
- P540. Can we predict response to cyclosporine as second line therapy in patients with severe acute colitis of inflammatory bowel disease?
- P541. Can we predict myelotoxicity development during thiopurine therapy for inflammatory bowel disease?
- P542. Crohn's Disease (CD) in the elderly - an IG-IBD study
- P543. Combined immunosuppression, corticoids and menopause have significant influence on bone mineral density of IBD patients. A prospective study
- P544. Bone mineral density measurement using dual energy X-ray in inflammatory bowel disease patients - Are we screening our patients for osteoporosis?
- P545. Bolus administration of steroid therapy is more favourable than the conventional use in preventing decrease of bone density and the increase of body fat percentage in patients with inflammatory bowel disease
- P546. Biological therapy in children and adolescents: infliximab and adalimumab, a comparison of their side effects
- P547. Biological agents for moderately-to-severely active ulcerative colitis in adults: a network meta-analysis of randomized controlled trials
- P548. Biological agents in Crohn's disease: When?
- P549. Azathioprine in the elderly - Is it tolerated and is it safe?
- P550. Azathioprine and lymphocyte count in paediatric inflammatory bowel disease
- P551. Association between haemoglobin levels, serum ferritin and faecal and serum markers of inflammation in patients with IBD
- P552. Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2
- P553. A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
- P554. A prospective assessment of antidrug antibody response over time by a new ELISA in patients with IBD treated with infliximab
- P555. A prospective, controlled, single center pilot study comparing the efficacy of infliximab maintenance therapy (5 mg/kg) every 8 vs. 10 weeks based on successive measurements of fecal calprotectin
- P556. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis
- P557. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy
- P558. Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease
- P559. Anti-tumour necrosis factor therapy improves initial resection rates in Crohn's disease
- P560. Anti-TNF is safe to stop in the second trimester of pregnancy in IBD women in remission
- P561. Anti-TNFalpha drug level measurements in IBD patients
- P562. Anti-TNF alpha blocking agents as a first-line therapy for IBD-associated pyoderma gangrenosum
- P563. Anti-TNF therapy reduces ionising radiation exposure in patients with ulcerative colitis
- P564. An innovative information technology tool to promote patient self-care - A web-based ‘IBD patient portal’
- P565. An experience of anti-TNF biosimilar, CT-P13 use: clinical efficacy, safety and interchangeability in inflammatory bowel disease; a pilot study
- P566. A matrix-based prediction model for primary response to infliximab in Crohn's disease patients
- P567. Allogeneic haematopoietic stem cell transplant (HSCT) for paediatric Crohn's disease: A case report
- P568. Adherence to quality measures for inflammatory bowel disease in Korea: Questionnaire study based on American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance Measures Set
- P569. Adalimumab was more effective in the patients with bio-naive and early Crohn's disease
- P570. Adalimumab therapy in children with Crohn’s disease previously treated with infliximab; a Dutch nationwide study
- P571. Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis
- P572. Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: Data from EXTEND
- P573. A combination of low-dose thiopurine and allopurinol (ThioComp) is long-term efficacious and well-tolerated in IBD patients
- P574. A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
- P575. A new tool for the surveillance of Crohn's perianal fistulae
- P576. A nurse-led one-hour infusion protocol of infliximab is safe and improves infusion service efficiency
- P577. Adverse effects of azathioprine in patients with inflammatory bowel disease (IBD)
- P578. Adalimumab as first-line anti-TNF treatment in pediatric Crohn's disease
- P579. A cost of care model for inflammatory bowel disease
- P580. A comparison of the pharmacokinetics of IMA-638, an anti-IL-13 monoclonal antibody, among healthy volunteers, subjects with asthma and ulcerative colitis patients
- P581. 5-ASA medication adherence comparison in Latvia and Estonia
- P582. Remission induction therapy with infliximab in patients with ulcerative colitis: Does tumour necrosis factor-α blockade per se explain its multiple actions?
- P583. Venous thromboembolism in Asian patients with inflammatory bowel disease
- P584. Vaccination and risk for inflammatory bowel disease: results of a meta-analysis
- P585. Treatment paradigm and natural course of ulcerative colitis between 1977–2012: a hospital-based cohort study from Korea
- P586. Time-to-diagnosis in inflammatory bowel disease
- P587. The prevalence of anaemia and iron deficiency in IBD inpatients and outpatients in Romania - an interim analysis on the first 120 patients
- P588. The prevalence and risk factors of low bone mineral density in a Slovak IBD cohort
- P589. The future of academic gastroenterology - insights from a Europe-wide survey of trainees
- P590. The features of IBD in young patients - evaluation of a batch of more than 1,000 patients
- P591. The clinical features and prognosis of Crohn's disease: A Korean multicenter nationwide cohort study
- P592. The characteristics of pediatric inflammatory bowel disease in Korea: comparison to EUROKIDS data
- P593. The incidence and natural history of paediatric Inflammatory Bowel Disease Unclassified in Scotland
- P594. The epidemiology of inflammatory bowel disease in children of Manitoba: 30 years' experience
- P595. Smoking in patients with IBD: increasing smoking rates and alarmingly low use of supportive measures to achieve smoking cessation - Data from the Swiss IBD cohort study
- P596. Risk factors for depression and anxiety in Crohn's disease
- P597. Reduced recurrence rates in Crohn's disease in the era of biological therapy: A 7-year population-based follow-up study of inflammatory bowel disease
- P598. Proton pump inhibitor use and risk of microscopic colitis - A nationwide Danish case–control study with 5751 cases
- P599. Prevalence of iron deficiency anemia and iron deficiency in a single center Turkish IBD cohort
- P600. Prevalence of anemia in children with inflammatory bowel disease in Russian Federation
- P601. Prevalence of anemia in Serbian patients with inflammatory bowel disease
- P602. Prevalence of inflammatory bowel disease in patients with spondyloarthritis and psoriasis. The AQUILES study
- P603. Prevalence and characteristics of extra-intestinal manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers
- P604. Prevalence and characteristics of dermatologic manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers
- P605. Presentation and progression of childhood-onset inflammatory bowel disease in northern Stockholm County
- P606. Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: A multicentre, case–control study
- P607. Prescription of enteral nutrition in paediatric Crohn's disease in Spain
- P608. Mesalazine suppository use - ECCO guideline vs. real life
- P609. Long-term prognosis of Crohn's disease and its temporal change between 1981–2012: a hospital-based cohort study from Korea
- P610. Life experiences of patients with perianal Crohn's fistulae
- P611. Is there an association between inflammatory bowel disease and Parkinson's disease?
- P612. Influence of mucosal healing in clinical course of ulcerative colitis
- P613. Incidence study and follow-up of a cohort of patients with inflammatory bowel disease (IBD) in Malaga (Spain)
- P614. Incidences and characteristics of intestinal and extraintestinal cancers in patients with inflammatory bowel disease: a population-based study
- P615. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000–2012
- P616. Impact of psychological factors in relapse of Crohn's disease
- P617. Impact of diagnostic delay on clinical outcome of Crohn's disease (CD)
- P618. Impact of depression on medication adherence in inflammatory bowel disease
- P619. Influence of coping strategies on the clinical course of inflammatory bowel disease: A prospective, observational cohort study
- P620. IBD in elderly Romanian patients: epidemiological and phenotypical characteristics
- P621. Health care consumption and treatment of ulcerative colitis in Stockholm County
- P622. Health care consumption and treatment of Crohn's disease in Stockholm County
- P623. Forty-year analysis of colonoscopic surveillance program for ulcerative colitis
- P624. Food and microbial IgG and IgA levels in the serum and feces of patients with inflammatory bowel disease and controls
- P625. Features of familial Crohn's disease: A comparative retrospective study
- P626. Extraintestinal manifestations in Romanian IBD patients - evaluation of a cohort of over 1000 patients
- P627. Exaggeration of physical symptoms in inflammatory bowel disease: Relation to depression, anxiety and quality of life
- P628. Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE Study)
- P629. Epidemiological features and disease related concerns of a large cohort of Italian patients with active Crohn's disease
- P630. Epidemiological and phenotypic characteristics of IBD patients in Romania - results of a nationwide hospital-based registry
- P631. ERAP-1 gene polymorphisms in Turkish patients with inflammatory bowel diseases and anyklosing spondylitis
- P632. Dietary practices in patients with inflammatory bowel disease - food for thought
- P633. Decision-making, counselling and course of pregnancy in female inflammatory bowel disease patients
- P634. Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998–2000 and 2007–2009
- P635. Comorbidity related hospitalizations in inflammatory bowel disease patients
- P636. Colorectal cancers in Indian patients with ulcerative colitis
- P637. Clostridium difficile infection rate in inflammatory bowel disease patients in a tertiary center in Israel
- P638. Characteristics of Gipsy pediatric patients with inflammatory bowel disease (IBD) based on the nationwide, prospective Hungarian pediatric IBD registry (HUPIR)
- P639. Caesarean section is associated with a younger age at IBD diagnosis and a higher proportion of Crohn's disease vs. ulcerative colitis - data from the Swiss IBD Cohort Study
- P640. A prospective population-based natural history registry of newly diagnosed IBD identifies high rates of severe disease and immunomodulator use after 1 year
- P641. Anxiety and depression in a prospective cohort of inflammatory bowel disease patients in Ireland
- P642. Anorectal cancer associated with Crohn's disease
- P643. Anemia in patients with inflammatory bowel disease - A nationwide cross-sectional study
- P644. Alcohol consumption within the Swiss IBD Cohort Study
- P645. A 10 year review of the death rate and cause of death of IBD patients
- P646. Clinical and epidemiological features of patients with inflammatory bowel disease and extraintestinal manifestations associated
- P647. 2-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease. The AQUILES study
- P648. What is the risk of malignancy at normal appearing mucosa in left-side ulcerative colitis patients?
- P649. Relationship between clinical characteristics and vitamin D receptor polymorphisms in Crohn's disease
- P651. Identification of new genetic variants related to thiopurine-induced myelotoxicity in inflammatory bowel disease (IBD) patients with normal thiopurines-methyltransferase (TPMT): a genome-wide association study
- P652. Global DNA methylation in inflammatory bowel disease
- P653. Genetic predictors of non reversible tissue damage in inflammatory bowel disease
- P654. Genetic susceptibility to orofacial granulomatosis
- P655. Gene expression alterations suggest that ulcerative colitis patients after restorative proctocolectomy have ileal disease
- P656. Fcgamma Receptor Type IIIa polymorphisms and their correlation with clinical outcome in patients with inflammatory bowel disease during a long term follow up
- P657. Effects of isotretinoin treatment on epigenetic programming in T cells
- P658. Effects of allopurinol on thiopurine metabolism and gene expression levels in HepG2 cells
- P659. Crohn's disease in an Irish population - a pilot genotype–phenotype analysis
- P660. Crohn's disease course is not different in familial than in sporadic cases: A case–control population-based study
- P661. Case–control study and meta-analysis of glutathione S-transferase polymorphisms in patients with inflammatory bowel disease
- P662. BAX, a novel susceptibility gene for Crohn's disease
- P663. Association of HIF1α pathway genes with relevant clinical subphenotypes in inflammatory bowel disease (IBD)
- P664. Association between genetic markers related to tight junctions and inflammatory bowel disease
- P665. A genome-wide association study identifies DSE-FAM26F as a risk locus for ulcerative colitis
- P666. Type 1 pili and long polar fimbriae are essential for induction of host–microbiota mutualism by adherent-invasive Escherichia coli, even in the presence of competing intestinal microbes
- P667. Low prevalence of Blastocystis sp. in active ulcerative colitis patients
- P668. Interspace microbiome profiling (IS-pro) enables to differentiate IBD subclasses and disease activity by specific loss of bacterial diversity
- P669. Inflammatory bowel disease and Epstein–Barr virus: analysis of our experience
- P670. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients
- P671. Effects of isotretinoin treatment on murine gut microbiota composition
- P672. Does the ileocecal valve functionally separate ileal and right-sided colon microbiota compositions?
- P673. Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis
- P674. DNA of Helicobacter species is present in patients with inflammatory bowel diseases
- P675. Alterations in composition and diversity of the intestinal microbiota in Korean Crohn's disease patients
- P676. Listeria monocytogenes infection in inflammatory bowel disease patients: case series
- NO001. Self-care among patients with inflammatory bowel disease - an interview study
- NO002. Symptom burden in individuals with inflammatory bowel disease: A mixed methods study
- NO003. Development of an assessment method based on Health Belief Model to identify patients with ulcerative colitis at high risk of non-adherence to aminosalicylates
- N001. Development of a simple stressometer to assess stress in inflammatory bowel disease patients
- N002. Using the National IBD Registry to prove the worth of the specialist nurse
- N003. Inflammatory bowel disease nursing in Canada: An examination of Canadian gastroenterology nurses and their role in IBD care
- N004. An evaluation of an IBD advice service: is it meeting its service aims?
- N005. The influenza vaccination in intestinal bowel disease patients increases after an interventional education nursery session
- N006. IBD patients' satisfaction related with nurse-driven outpatient clinic
- N007. Survey of factors determining adherence to follow up in IBD patients
- N008. Audit into patient opinion of an inflammatory bowel disease nurse led virtual telephone follow-up clinic
- N009. The effects of IBD nurse consultations on patient's compliance
- N010. A review of nursing consultancy to control patients with inflammatory bowel disease treated with thiopurines: Analysis and implementation of improvements
- N011. Therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease (IBD) in a Dutch peripheral hospital. Indications and therapeutic consequences
- N012. Role of ambulatory nursery patient education in adalimumab therapy
- N013. Experience with metronidazole topical therapy to treat dermatological lesions related to inflammatory bowel disease (IBD)